News

Incidence of HPV-associated cancers on the rise


 

FROM MORBIDITY AND MORTALITY WEEKLY REPORT

References

The incidence of human papillomavirus–associated cancers is increasing in the United States, but many of these cases could be prevented by the HPV vaccine, investigators from the Centers for Disease Control and Prevention report.

Between 2008 and 2012 the incidence of HPV-associated cancers was 11.7/100,000 persons, up from 10.8/100,000 persons during the previous 4-year period, according to data from population-based cancer registries. An average of 38,793 HPV-associated cancers were diagnosed in the most recent period, 30,700 (79%) of which can be attributed to HPV. Of those, 28,500 cancers are of HPV types that are preventable with the 9-valent HPV vaccine, reported Laura J. Viens, MD, and her associates.

©xrender/Thinkstock

Among the HPV-associated cancers, an average of 11,7771 cervical cancer cases were diagnosed each year. Rates of cervical cancer per 100,000 persons were higher among blacks (9.2) than among whites (7.1), and among Hispanics (9.7) than non-Hispanics (7.1).

“Increasing [HPV] vaccination coverage could decrease the cancer incidence and disparities in the United States,” the investigators concluded.

Find the full report from Morbidity and Mortality Weekly Report here

acruz@frontlinemedcom.com

Recommended Reading

ACIP votes on incorporating 9-valent HPV vaccine into recommendations
MDedge Hematology and Oncology
New 9-valent HPV vaccine is efficacious, well tolerated
MDedge Hematology and Oncology
Gardasil vaccination reduces cervical dysplasia in teen years
MDedge Hematology and Oncology
PAS: Texting beats phone reminders for HPV vaccine completion
MDedge Hematology and Oncology
AACR: HPV vaccine may protect some women with prior exposure
MDedge Hematology and Oncology
HPV vaccine coverage continues to lag
MDedge Hematology and Oncology
Provider hesitancy hamstrings HPV vaccine uptake
MDedge Hematology and Oncology
College students report perceived barriers to HPV vaccine
MDedge Hematology and Oncology
Primary care residents’ approach to HPV vaccine vary by specialty
MDedge Hematology and Oncology
HPV vaccine doesn’t provide herd immunity or crossprotection
MDedge Hematology and Oncology